KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Cash & Equivalents data on record, last reported at $177.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 44.4% year-over-year to $177.7 million; the TTM value through Dec 2025 reached $177.7 million, down 44.4%, while the annual FY2025 figure was $177.7 million, 44.4% down from the prior year.
  • Cash & Equivalents reached $177.7 million in Q4 2025 per ACAD's latest filing, down from $258.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $319.6 million in Q4 2024 and bottomed at $94.6 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $193.9 million, with a median of $183.2 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 75.94% in 2021, down 79.08% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $147.4 million in 2021, then fell by 22.1% to $114.8 million in 2022, then surged by 64.27% to $188.7 million in 2023, then surged by 69.4% to $319.6 million in 2024, then plummeted by 44.4% to $177.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $177.7 million in Q4 2025, $258.0 million in Q3 2025, and $253.6 million in Q2 2025.